Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Q4 2023 Syndax Pharmaceuticals Inc Earnings Call Transcript

Feb 27, 2024 / 09:30PM GMT
Release Date Price: $24.41 (+0.14%)
Operator

Good day everyone, and welcome to the Syndax Fourth Quarter and Full Year 2023 earnings conference call. Today's call is being recorded. (Operator Instructions)

At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.

Sharon Klahre
Syndax Pharmaceuticals, Inc. - Head of IR

Thank you, operator. Welcome and thank you all for joining us today for a review of Syndax Fourth Quarter and Full Year 2023 financial and operating results. Me Sharon Klahre and with me this afternoon to provide an update on the company's progress and discuss financial results, our Michael Metzger, Chief Executive Officer, Dr. Neil Gallagher, President and Head of R&D, and Keith Goldan, Chief Financial Officer.

Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer, and Dr. Anjali Ganguli, Chief Business Officer.

This call is accompanied by a slide deck that's been posted on the investor page of the company's website. You can now

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot